Non-amyloid fibrillary glomerulopathy

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:97566N03.6
Who is this for?
Show terms as
1Active trials3Specialists8Treatment centers

Where are you in your journey?

ℹ
UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Also known as:

Congo red-negative amyloidosis-like glomerulopathyNon-amyloid fibrillary glomerulonephritis
Orphanet ↗NORD ↗

FDA & Trial Timeline

1 event
Jun 2024Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

Mayo Clinic — PHASE2

TrialRECRUITING

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Treatments

No FDA-approved treatments are currently listed for Non-amyloid fibrillary glomerulopathy.

1 clinical trialare actively recruiting — trials can provide access to cutting-edge therapies.

View clinical trials →

Clinical Trials

1 recruitingView all trials with filters →
Phase 21 trial
Obinutuzumab in Treatment of Fibrillary Glomerulonephritis
Phase 2
Actively Recruiting
PI: Ladan Zand (Mayo Clinic) · Sites: Rochester, Minnesota · Age: 18–99 yrs
View on ClinicalTrials.gov ↗I'm interested →

Specialists

3 foundView all specialists →
LZ
Ladan Zand
ROCHESTER, MN
Specialist
PI on 1 active trial
SM
Stephen B. Erickson, M.D.
Specialist
PI on 2 active trials
FM
Fernando Fervenza, MD
ROCHESTER, MN
Specialist
PI on 3 active trials

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center ↗

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center ↗

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program ↗

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site ↗

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site ↗

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site ↗

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine ↗

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program ↗

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Non-amyloid fibrillary glomerulopathy.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Non-amyloid fibrillary glomerulopathyForum →

No community posts yet. Be the first to share your experience with Non-amyloid fibrillary glomerulopathy.

Start the conversation →

Latest news about Non-amyloid fibrillary glomerulopathy

Disease timeline:

New recruiting trial: Obinutuzumab in Treatment of Fibrillary Glomerulonephritis

A new clinical trial is recruiting patients for Non-amyloid fibrillary glomerulopathy

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Non-amyloid fibrillary glomerulopathy

Are there clinical trials for Non-amyloid fibrillary glomerulopathy?

Yes — 1 recruiting clinical trial is currently listed for Non-amyloid fibrillary glomerulopathy on UniteRare. See the clinical trials section on this page for phase, sponsor, and site details sourced from ClinicalTrials.gov.

Which specialists treat Non-amyloid fibrillary glomerulopathy?

3 specialists and care centers treating Non-amyloid fibrillary glomerulopathy are listed on UniteRare, sourced from ClinicalTrials.gov principal investigators, published research, and the NPPES NPI registry.